Financial Performance - The net loss for the nine months ended September 30, 2024, was $8,880,935, compared to a loss of $3,936,284 for the same period in 2023, indicating a 126% increase in losses[7]. - For the three months ended September 30, 2024, the net loss attributable to shareholders was $2,959,216, compared to a net loss of $2,963,692 for the same period in 2023[60]. - The basic and diluted net loss per share attributable to shareholders for the three months ended September 30, 2024, was $(0.31), while it was $(1.47) for the same period in 2023[60]. Assets and Equity - Total assets increased to $5,720,909 as of September 30, 2024, compared to $1,893,057 as of December 31, 2023, representing a growth of 201%[3]. - Shareholders' equity increased to $3,492,104 as of September 30, 2024, from $1,111,448 at the end of 2023, representing a growth of 214%[3]. - Cash and cash equivalents rose to $5,306,159 from $1,719,338, marking an increase of 208%[3]. Expenses - Operating expenses for the nine months ended September 30, 2024, totaled $8,830,197, up from $885,040 in the same period of 2023, reflecting a significant increase of 895%[7]. - Research and development expenses for the nine months ended September 30, 2024, were $2,162,680, compared to $159,083 in 2023, an increase of 1,613%[7]. - General and administrative expenses for the three months ended September 30, 2024, totaled $2,201,911, a significant increase from $186,418 in 2023[61]. Share Capital and Issuance - The company issued 1,461,250 common shares, raising $5,470,000 during the period[10]. - The company issued 1,461,250 common shares on June 28, 2024, as part of a private placement, raising total proceeds of $5,845,000 at $4.00 per share[51]. - As of September 30, 2024, the total number of common shares outstanding increased to 10,846,721, with a total share capital of $30,516,801[50]. - The company's share capital increased to $30,516,801 as of September 30, 2024, from $19,835,839 as of December 31, 2023[69]. Debt and Obligations - The company issued convertible notes amounting to $5,172,500 on May 3, 2024, with a 10% annual interest rate and a maturity date of December 31, 2025[43]. - On June 28, 2024, all convertible note holders converted their notes into 1,308,798 common shares, including $40,563 in cash interest and $38,462 in accrued interest[45]. - The lease obligations increased to $348,971 as of September 30, 2024, with additions of $356,784 and interest accretion of $27,227[40]. - The total undiscounted lease payments payable as of September 30, 2024, amounted to $398,181, with a present value impact of $49,210[42]. Other Financial Information - The company recognized share-based compensation of $580,629 for the nine months ended September 30, 2024, compared to $nil in the previous year[55]. - The company has 887,500 share options outstanding as of September 30, 2024, with a weighted average exercise price of C$1.63[55]. - The company has an obligation to pay an annual license maintenance fee of $5,000 until sales from products under the license occur, with no sales made as of September 30, 2024[63]. - The company recognized $7,720 and $39,689 in annual maintenance and patent legal expenses related to the license agreement during the three and nine months ended September 30, 2024[63]. - The company incurred a listing expense of $2,550,665 related to the reverse takeover transaction completed on September 29, 2023[17]. Cash Flow - The company reported a net change in cash of $3,586,821 during the nine months ended September 30, 2024, compared to $4,840,293 in the same period of 2023[13]. Accounting Standards - The company has not adopted any new accounting standards that would significantly impact its financial statements as of January 1, 2024[33]. Initial Public Offering - On November 15, 2024, the company closed its initial public offering in the United States of 970,000 units at a price of $4.125 per unit[73]. Finance Income and Expense - Finance expense (income), net for the three months ended September 30, 2024, was $(46,531), compared to $186,214 in 2023[62].

As filed with the U.S. Securities and Exchange Commission on October 31, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 9 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Cl ...

As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 8 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective dat ...

As filed with the U.S. Securities and Exchange Commission on October 15, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the U.S. Securities and Exchange Commission on September 30, 2024. Registration No. 333-279771 Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Suite 3400 - 100 King St W Toronto, ON M5X 1A4, Canada ...

As filed with the U.S. Securities and Exchange Commission on September 26, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) ...

As filed with the U.S. Securities and Exchange Commission on September 23, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) ...

As filed with the U.S. Securities and Exchange Commission on August 23, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Cla ...

As filed with the U.S. Securities and Exchange Commission on August 9, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.2 TO REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) Ontario, Canada 2834 Not Applicable (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identificatio ...

As filed with the U.S. Securities and Exchange Commission on July 15, 2024. Registration No. 333-279771 Ontario, Canada 2834 Not Applicable (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specifie ...